Most patients with immediate, potentially allergic reaction to Pfizer-BioNTech or Moderna mRNA COVID-19 vaccine tolerate second dose<\/em><\/p>\n<\/h3>\n <\/b><\/p>\n <\/b><\/p>\n THURSDAY, July 29, 2021 (HealthDay News) — Most patients with an immediate and potentially allergic reaction to the first dose of the Pfizer-BioNTech or Moderna mRNA COVID-19 vaccine tolerate a second dose, according to a research letter published online July 26 in JAMA Internal Medicine<\/em>.<\/p>\n Matthew S. Krantz, M.D., from the Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues examined the safety of the second dose of the Pfizer-BioNTech or Moderna vaccine in those with a history of immediate and potentially allergic reactions to the first dose. Data were included for 189 participants with mRNA COVID-19 vaccine first-dose reactions: 130 to Moderna and 59 to Pfizer-BioNTech; 32 of these reactions met anaphylaxis criteria. One hundred fifty-nine of these participants received a second dose.<\/p>\n The researchers found that 47 of the patients (30 percent) received an antihistamine premedication before the second dose. All 159 patients tolerated the second dose, including 19 with first-dose anaphylaxis. Thirty-two of the patients (20 percent) reported immediate and potentially allergic symptoms that were linked to the second dose; these were self-limited, mild, and\/or resolved with antihistamines alone.<\/p>\n “Second dose tolerance following reactions to the first dose argues that either many of these initial reactions are not all truly allergic reactions, or supports an allergic, but non-immunoglobulin E-mediated mechanism in which symptoms can typically be abated with premedications,” the authors write.<\/p>\n One author disclosed financial ties to the pharmaceutical and medical technology industries.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n